CHIESI FARMACEUTICI S.P.A.
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- -
- Established
- 1935-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.chiesigroup.com
TRIple in Asthma hiGh strenGth vErsus Ics/Laba hs and tiotRopium (TRIGGER)
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Drug: CHF 1535 200/6 µgDrug: CHF 5993 200/6/12.5 µgDrug: CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg
- First Posted Date
- 2016-02-08
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 1433
- Registration Number
- NCT02676089
- Locations
- 🇦🇷
Chiesi Clinical Trial Site 432702, Ciudad Autónoma de Buenos Aires, Argentina
🇪🇸Chiesi Clinical Trial Site 724703, Badajoz, Spain
🇦🇷Chiesi Clinical Trial Site 432705, Mar Del Plata, Argentina
2-arm Parallel Group Study of Fixed Combination of CHF 5993 vs Ultibro® in COPD Patients
Phase 3
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Drug: CHF 5993 + Ultibro matched placeboProcedure: Central spirometryOther: COPD assessment testProcedure: Local laboratory AssessmentsOther: Saint George's Respiratory QuestionnaireOther: EXACT-pro questionnaire
- First Posted Date
- 2015-10-20
- Last Posted Date
- 2021-10-29
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 1532
- Registration Number
- NCT02579850
- Locations
- 🇮🇹
Chiesi Farmaceutici S.p.A., Parma, Italy
Effect of OC000459 on Eosinophilic Airway Inflammation in Severe Asthma
- First Posted Date
- 2015-09-25
- Last Posted Date
- 2019-08-29
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 40
- Registration Number
- NCT02560610
- Locations
- 🇬🇧
University of Oxford, Oxford, Oxfordshire, United Kingdom
Pharmacokinetic Study of ENVARSUS in Adult De-novo Kidney Transplant Patients
Phase 4
Completed
- Conditions
- Organ or Tissue Transplant; Complications
- Interventions
- First Posted Date
- 2015-07-16
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 75
- Registration Number
- NCT02500212
- Locations
- 🇫🇷
Clinique de Nephrologie CHU Grenoble, Grenoble, France
🇫🇷Nephrology department CHU de Saint-Etienne Hospital Nord, Saint Etienne, France
🇫🇷Service de Nephrologie, Montpellier, France
Non Inferiority of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) Versus Combination of Fluticasone Furoate (FlF)/Vilanterol (VI) + Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD)
Phase 3
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: FlF/VI + Tiotropium
- First Posted Date
- 2015-06-10
- Last Posted Date
- 2021-10-29
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 1479
- Registration Number
- NCT02467452
- Locations
- 🇭🇺
Erzsebet Gondozohaz, Godollo, Hungary
A Double Blind, Randomized, Controlled Study to Evaluate CHF 5633 (Synthetic Surfactant) and Poractant Alfa in Neonates With Respiratory Distress Syndrome (RDS) (POC)
Phase 2
Completed
- Conditions
- Respiratory Distress Syndrome, Newborn
- Interventions
- First Posted Date
- 2015-05-22
- Last Posted Date
- 2021-08-13
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 123
- Registration Number
- NCT02452476
- Locations
- 🇺🇸
Martha Naylor, Greenville, North Carolina, United States
🇺🇸West Virginia University, Morgantown, West Virginia, United States
🇺🇸Connecticut Children's Medical Center, Hartford, Connecticut, United States
Multicentre, Open Label, Randomized, Two-arm, Parallel-group Study to Assess Efficacy and Safety of ENVARSUS® Compared With Tacrolimus Used as Per Current Clinical Practice in the Initial Maintenance Setting in de Novo Kidney Transplant Patients
Phase 4
Completed
- Conditions
- End Stage Renal Disease
- Interventions
- First Posted Date
- 2015-05-04
- Last Posted Date
- 2018-04-13
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 428
- Registration Number
- NCT02432833
- Locations
- 🇮🇹
Chiesi farmaceutici Spa, Parma, Italy
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF6001
Phase 1
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Multiple Ascending Dose (MAD)Drug: Single Ascending Dose (SAD)
- First Posted Date
- 2015-03-12
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 48
- Registration Number
- NCT02386761
- Locations
- 🇬🇧
Quotient Clinical, Nottingham, UK, United Kingdom
Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and Lung Bioavailability of CHF 5993 pMDI Combination in Healthy Volunteers
Phase 1
Completed
- Conditions
- Asthma
- Interventions
- Drug: CHF 5993 HS 200/6/25 pMDIDrug: CHF 5993 MS 100/6/25 pMDIDrug: CHF 5993 HS 200/6/25 pMDI + Charcoal BlockDrug: CHF 5993 MS 100/6/25 pMDI + Charcoal BlockDrug: Placebo pMDI
- First Posted Date
- 2015-02-10
- Last Posted Date
- 2021-07-02
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 50
- Registration Number
- NCT02359292
- Locations
- 🇧🇪
SGS CPU Antwerpen, Antwerpen, Belgium
Efficacy of LAMA Added to ICS in Treatment of Asthma
Phase 2
Completed
- Conditions
- Asthma
- Interventions
- Drug: CHF 5259 12.5 µgDrug: CHF 5259 placebo
- First Posted Date
- 2014-11-20
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 98
- Registration Number
- NCT02296411
- Locations
- 🇩🇪
Chiesi Clinical Trial Site 0202, Leipzig, Germany
🇩🇪Chiesi Clinical Trial Site 0206, Magdeburg, Germany
🇳🇱Chiesi Clinical Trial Site 0404, Assen, Netherlands
© Copyright 2025. All Rights Reserved by MedPath